Navigation path

Themes
Agriculture & food
Energy
Environment
ERA-NET
Health & life sciences
Human resources & mobility
Industrial research
Information society
Innovation
International cooperation
Nanotechnology
Pure sciences
Research infrastructures
Research policy
Science & business
Science in society
Security
SMEs
Social sciences and humanities
Space
Special Collections
Transport

Countries
Countries
  Argentina
  Australia
  Austria
  Belgium
  Benin
  Brazil
  Bulgaria
  Canada
  Chile
  China
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Egypt
  Estonia
  Finland
  France
  Georgia
  Germany
  Ghana
  Greece
  Hungary
  Iceland
  India
  Ireland
  Israel
  Italy
  Japan
  Kazakhstan
  Kenya
  Korea
  Latvia
  Lithuania
  Luxembourg
  Malaysia
  Malta
  Mexico
  Montenegro
  Morocco
  Namibia
  Netherlands
  Nigeria
  Norway
  Peru
  Poland
  Portugal
  Romania
  Russia
  Serbia
  Slovakia
  Slovenia
  South Africa
  Spain
  Swaziland
  Sweden
  Switzerland
  Taiwan
  Tanzania
  Thailand
  Tunisia
  Turkey
  Ukraine
  United Kingdom
  United States


   Success Stories

Last Update: 02-07-2014  
Related category(ies):
Health & life sciences

 

Countries involved in the project described in the article:
Denmark  |  France  |  Germany  |  Italy  |  Netherlands  |  Spain  |  Sweden  |  United Kingdom
Add to PDF "basket"

Spotting inherited heart disease before it strikes

Idiopathic dilated cardiomyopathy (DCM) is a type of heart disease in which the organ's muscle becomes weaker. It can lead to heart failure and ventricular arrhythmia (a type of irregular heart beat) or even sudden death. The EU-funded INHERITANCE project has provided a better understanding of the genetic causes of DCM, while developing diagnostic and therapeutic strategies for patients.

image of read heart © Brian Jackson - Fotolia.com

DCM affects one in 2500 adults, with an annual incidence of between 5% and 8% per 100 000,” says INHERITANCE coordinator Professor Eloisa Arbustini of the Foundation IRCCS Policlinico San Matteo. “It is one of the leading causes of heart failure due to systolic dysfunction, being responsible for 10 000 deaths per year in Europe, and it is the most common indication for cardiac transplantation in adolescents and adults.”

Early diagnosis and management of the disease is fundamental, but in spite of the fact that it is inherited in up to half of all cases, few patients are aware of the familial risk and less than 1% get genetic testing.

Familial DCM is “genetically heterogeneous”, says Arbustini. That means several different genes may cause the disease. INHERITANCE researchers have worked to characterise different types of DCM, and they undertook genetic studies to explore the molecular makeup behind the different mutations that cause the disease.

Arbustini says thousands of patients with DCM throughout Europe took part in the research project. In addition, using some of the most innovative, next-generation genetic sequencing techniques, researchers have analysed 84 genes in more than 700 of those patients.

The results have enabled successful pre-clinical and pre-symptomatic diagnosis, meaning researchers can identify family members at risk before they develop the disease.

They have also developed ground-breaking, family-tailored and optimised clinical and genetic work-up, enabling a more cost-effective use of medical resources.

“Over the course of three years,” says Arbustini, “we have obtained important new information with immediate relevance to everyday clinical practice. The greatest contribution has been our characterisation of patients with ‘laminopathies’, a subtype of DCM caused by mutations in the gene encoding for the nuclear envelope protein.”

This kind of DCM, she says, affects some 8% of all cases and carries a high risk of ventricular arrhythmias, even in the early phases of the disease.

“Another major achievement of INHERITANCE has been to provide policy makers with a healthcare model that can be applied across the continent,” she says.

Using this model to diagnose and care for families identified with genetic DCM allows doctors to provide tailored monitoring, treatment and preventive care, reduce discomfort for patients and cost compared to other treatment. Patients can receive treatment as outpatients and avoid unnecessary hospitalisation.

Arbustini says the subject of the study, familial DCM, is not only an important healthcare problem in its own right but can also serve as a model for developing improved and tailored treatments for other inherited diseases.

28th February 2014 Rare Diseases Day 2014

Project details

  • Project acronym: INHERITANCE
  • Participants: Italy (Coordinator), France, UK, Nederlands, Spain, Denmark, Germany, Sweden
  • FP7 Proj. N° 241924
  • Total costs: € 4 028 394
  • EU contribution: € 2 870 791
  • Duration: January 2010 - December 2013

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also

Project web site

Project information on CORDIS

Contacts
Unit A1 - External & internal communication,
Directorate-General for Research & Innovation,
European Commission
Tel : +32 2 298 45 40
  Top   Research Information Center